RUDN University mathematicians developed a model of the movement of immune cells
RUDN University mathematicians developed a model of the movement of immune cells
Mathematicians from RUDN University have developed a computational model that allows predicting the mobility of T-lymphocytes, immune cells that recognise and destroy viruses. The model will help, in particular, in the treatment of the immune system disorders, including those that can lead to cancer, and in the development of HIV vaccines.

Antibodies to HIV infection appear in the body about a month after it has been infected. Prior to that, the immunodeficiency virus can freely circulate and multiply in the body. The vaccine should trigger immune responses at an early stage, when the virus can still be destroyed, or its reproduction effectively restrained. To effectively fight viruses, T-lymphocytes need to find infected cells within 18 hours after the latter entered the body, that is, before the moment when the viral particles begin to be released from the infected cells and spread. To create a vaccine, it is necessary to learn how T-lymphocytes move and how they find virus-infected cells. Vitalii Volpert, head of the RUDN University Interdisciplinary center for Mathematical modelling in Biomedicine, and his colleagues created a computer model of the movement of immune cells to find that out. Researchers from the G.I. Marchuk Institute of Numerical Mathematics RAS, Moscow Institute of Physics and Technology, Institute for Problems in Mechanical Engineering RAS, Uppsala University (Sweden), and Pompeu Fabra University (Spain).

Immunologists know that T-lymphocytes move in the intercellular space not randomly, but in search of target cells, that is, cancer cells or cells infected with a virus. To understand how they do it, RUDN University mathematicians created a computer model of the movement of T-lymphocytes.

Usually, conditions under which cells exist in the body and laws of physics which govern them are taken into account for modelling cellular processes. The mathematicians from RUDN University also used real experimental data on the mobility of T cells in their model, among other things. In addition, the model takes into account the interaction of T cells with other cells of the immune system: DC dendritic cells that activate the immune response, CD4 helper cells, and CD8 effector cells that destroy infected cells. To study how to increase the efficiency of the immune response, the RUDN University mathematicians kept changing the parameters of the model by adjusting the “frequency” of different types of immune cells, that is, the proportion of each type in the population, for example, the proportion of cytotoxic T-lymphocytes that “specialise” in searching for cells infected with HIV.

The mathematical modelling showed that 5% frequency of HIV antigen-specific cytotoxic T cells is sufficient to detect infected cells within 18 hours, that is, before the immunodeficiency virus particles are released from the infected cells. If the share of cytotoxic T-lymphocytes is increased from 0.04% to 5%, the model shows that the likelihood of detecting HIV-infected cells within 24 hours also increases by roughly 5 times, from 7-34% to 84-100%.

The results will facilitate, in particular, creation of vaccines against HIV, drugs for autoimmune diseases as well as other disorders associated with immune system dysfunctions. The model created by the RUDN University mathematicians helps to predict the effectiveness of the immune response, determines what characteristics of the behaviour of immune cells help them to stop the development of the disease, and determines the conditions under which the body can fight the infection before the virus begins to multiply intensively.

The study was published in Frontiers in Immunology.

News
All news
Science
06 Jul
A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A chemist from RUDN University has created platinum complex compounds that are superior in activity to cisplatin, the drug for the treatment of tumour diseases. The new compounds turned out to be also less toxic to healthy cells.